Seven essential drugs will become cheaper under new pricing rules.
Russia’s antitrust regulator has approved price reductions for seven widely used medicines included in the country’s list of vital drugs, following recent regulatory changes.
The Federal Antimonopoly Service (FAS) saidthe move was enabled by a government decree that took effect on February 24, 2026, updating the official list of vital and essential medicines (VED). The revised framework allows authorities to regulate prices across all forms of listed drugs.
The regulator reviewed manufacturer pricing proposals for treatments covering pain relief, wound care, cancer, respiratory illnesses, infectious and inflammatory diseases, and cardiovascular conditions. Following an economic assessment, FAS approved lower prices across all seven drugs.
Price reductions include 37% for Polyoxidonium, 11% for hydrogen peroxide spray, 45% for perindopril, and nearly 50% for morphine. Prices for the cancer drug Calquence T were set 13% below the lowest level in reference countries, while Symbicort Rapihaler was priced 14% below its 2025 average.
FAS noted that previously only certain forms of medicines were subject to state price controls, while other variations could be priced freely by manufacturers.
Source: Pharmvestnik
